The path from a potential break through to a successful global brand depends on securing the necessary resources, expertise and experiences.
This is increasingly achieved through close collaboration between partners who share a common vision and complementary strengths.
We want to provide our partners a global reach and establish their products as leaders in PAKISTANI market.
At this time we are seeking partners for in licensing of products for Pakistan. Our interest is in, Oncology, Hepatology, gastroenterology, diagnostic, disposables & other highly specialized products.
Youcare Pharmaceutical Group is a multiple-medical and pharmaceutical enterprise integrated with science, industry and trade. It takes medical research and development as core, makes self-made brands as main, and operates raw material medicines, western and Chinese medicines, health care products, medical equipments and contraceptives.
The group was founded in 1988 initially and registered in Beijing in 2001. Youcare Pharmaceutical Group has established 13 subsidiary companies at home including 1 research institute, 4 GMP standard pharmaceutical factories and 8 medical logistics companies and about 30 offices in domestic provinces and cities and liaison offices abroad to form an open development structure integrated with research, manufacture, supply and sale
Beijing SL Pharmaceutical Co., Ltd, well known as “SL PHARM”, is a high biotechnology-pharmaceutical company, mainly engages in developing and marketing gene engineering drugs. The company, founded in December 1994, was originally as the name “Beijing BaiLuyuan Bio-Pharmaceutical Co., Ltd”, and changed the name as “Beijing SL Pharmaceutical Co., Ltd.” in 1998. It became a Joint-Stock Company Limited in August 2000 and was listed in Chinese Stock Exchange in 2004.
SL Pharm is located in Haidian District, Beijing, China. Registration capital of the company is CNY 82 million, and net asset is about CNY 150 million. The plant is located in Beijing Badachu High-tech Zone，which occupies 12,000 square meters, and workshops are well equipped with GMP authenticate production lines. Annual production capacity of the manufacturer reaches 20 millions of pharmaceutical injections, and 200 millions of oral solid pharmaceutical products (tablets). All products have got GMP Authentication issued by Chinese State Food & Drug Administration (SFDA). Management is performed according to the requirements of international GMP standards from workshops, equipments, raw or auxiliary materials, packing materials to production, quality and hygiene.
The staff of SL Pharm is more than 200 in totals, of which 81% have BS or above degree, and 93% have qualified technical expertise. General Manager, Dr. Mingbo Xu, is a biopharmacologist, an expert in bioengineering technology and molecular biology. As an excellent scientist, Dr. Xu is awarded Government Special Subsidy for his outstanding contribution.
In the last ten years company developed and marketed more than 40 kinds of new drugs. Among these drugs, 2 are certificated as the 1st class drugs and 11 as the 2nd class drugs. In addition, more than 20 kinds of new products are in the registration pipeline.
The company was established in 1992, registered in Haidian District, Beijing. It belongs to pharmaceutical manufacturing industry; the main business is drug production and drug distribution. The main products are magnetic resonance contrast agent, Gd-DTPA injection, non-ionic iodine contrast medium iohexol injection and oral contrast agents ferric ammonium citrate effervescent granules. The initiators are three natural persons and one technology Investment Company in Beijing. Registered capital before the issuance of shares is 38.39 million Yuan.
In 2007, 2008 and 2009, revenue was respectively 232 million Yuan, 177 million Yuan and 217 million Yuan; net profit was 27.66 million Yuan, 26.05 million Yuan and 34.86 million Yuan; net profit growth rate was 125.1%, -5.84 % and 33.81%.
The company was listed on October 30, 2009, and issued 17 million shares at an issue price of 17.86 Yuan, at the same day it raised 272 million Yuan, the highest price the day had reached 51.6 Yuan, after dividend program of 10 shares for another 5 shares with 1.3 Yuan cash dividend, and today’s stock price is 21.12 Yuan; in 2009, sales revenue of contrast agent was 105 million Yuan, and drug distribution was 105 million Yuan; East and North China are the main sales market. In 2009 net assets yield rate was 8.04%, and earnings per share were 0.65 Yuan.
The company’s leading products are mainly concentrated in the areas of contrast agent. If there are market fluctuations in the contrast agent market resulting from the Government’s mandatory price adjustment, the emergence of new alternative products and other factors, the company’s future operating results, profitability and growth will be severely affected. With the reform of drug prices, medical insurance system reform, and other policies, regulations or the introduction of the adjustment, the company’s leading product faces the risk of certain price reductions; Second, with the increasing competition in contrast agent market and the further promotion and reform of the hospitals’ pharmaceutical procurement in the future, the company still faces the risk of price reduction, which may lead to the profit reduction.
In the next three years, the company will fully utilize the technical superiority, product superiority, quality advantage, brand advantage and supply of raw materials the company has obtained, taking the existing production of contrast agent series products and expanded product line as its basis, through the integration of the market, technology, capital and other resources, continue to adjust and optimize the product structure of contrast agent, maintain the company’s leading position in contrast agent market segment, and strive to make the company the most competitive professional manufacturers in the contrast agent market to become the leading modern contrast agent series products manufacturer. At the same time, appropriately expand production and sales areas for the development of anti-anxiety medicine as the company’s new profit growth point, and strive to make Jiuwei Zhenxin Granule the first brand in anti-anxiety medicine, one of major sources of revenue and profits, making the company occupy a place in the anti-anxiety drug market.
Hongda
NO.39 SOUTH SHENGLI RD JINXIAN COUNTY JIANGXI PROVINCE,CHINA
Jiangxi Hongda Medical Equipment Group Co., Ltd. is certified by the State Food and Drug Administration. We specialize in manufacturing sterile medical instruments and supplies for one time use.
Our products cover 8 categories and include complete varieties. These are infusion and transfusion sets, syringes, puncture sets (needles), medical pouches, examination and assistant appliances, anesthesia items, medical catheters, and sanitation expendables.
With well-trained management personnel and advanced equipment, our output capacity has reached such that we can meet market demands for these products. Our company employs a staff of more than 5,000 people, making us a leading medical company in China for our large annual output and sound sales. We have a sales network throughout China, and export to Southeast Asia, South America, the Middle East, and Europe.
Our company has a complete quality assurance system according to CE, ISO9001 and ISO13845 certifications. We believe that "today's quality decides tomorrow's market," and therefore emphasize user satisfaction for our company's survival. Persisting in the most reasonable prices to reflect the market, we sincerely appreciate more customers to help create an even more professional Hongda brand.
|
